Brexucabtagene Autoleucel — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

3 Recruiting

6 Completed trials

5 Sponsors

10 Countries

Phase II

Phase IV

Phase II: 8 Phase IV: 2 Phase I (Other): 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

Mantle cell lymphoma refractory 2 Mantle cell lymphoma 1 Mantle cell lymphoma stage III 1 Mantle cell lymphoma stage II 1 Mantle cell lymphoma recurrent 1 Mantle cell lymphoma stage IV 1

Sponsors using this IMP

Kite Pharma Inc. 7 Centre Hospitalier Universitaire De Saint Etienne 1 Fondazione IRCCS Istituto Nazionale Dei Tumori 1 Klinikum der Universitaet Muenchen AöR 1 Universitair Ziekenhuis Gent 1

All trials

11 total

Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy Pending

2025-524278-40-00 Phase IV 1 country Universitair Ziekenhuis Gent
CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting

2022-502405-15-01 Phase II 5 countries Klinikum Der Universitat Munchen AöR
Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector C… Recruiting

2024-515328-35-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Recruiting

2023-507041-28-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501259-10-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended

2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501262-21-00 Phase II 7 countries Kite Pharma Inc.
A Study Evaluating the Safety and Efficacy of KTE-X19 in pediatric and adolescent Subjects with Relapsed/Refractory B-precursor Acute Lympho… Ended

2023-509440-97-00 Phase I (Other) 6 countries Kite Pharma Inc.
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended

2023-506641-35-00 Phase II 4 countries Kite Pharma Inc.
A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial respon… Expired

2022-502907-31-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori

Showing 1–11 of 11 trials

← All drugs A–Z